Antiphospholipid syndrome in patients with acute myocardial infarction

Background: Antiphospholipid syndrome (APS) is a known cause of thrombotic disorders, including Acute Myocardial Infarction (AMI). Although the incidence of APS in AMI patients it’s not known, it can be an important cause of myocardial infarction especially in young patients. Objectives: The aim of this study is to evaluate the relationship between antiphospholipid syndrome and acute myocardial infarction in patients presented at cardiac emergency and cardiac reanimation at UHC Mother Teresa, Tirana, Albania Methods: This is an observational study which included all patients from 23 to 45 years old presented as Acute Myocardial Infarction at our hospital from 10 december 2016–10 december 2017. In this period, there were diagnosed with AMI 61 patients fulfilling the inclusion criteria of the study: 37 males and 24 females. Besides the usual laboratory tests, all patients included in the study were completed with the titration of APS autoantibodies (Anti-cardiolipin, Lupus anticoagulant, β2 glycoprotein 1 antibodies). If positive, according to diagnosis guidelines, the tests were repeated after 12 weeks. Results: Of 61 patients with AMI, 17 patients were positive for Antiphospholipid Syndrome at the first test and after 12 weeks, APS ws confirmed in 15 patients (24.6%): 10 females (67%) and 5 males (33%). Three of the patients diagnosed with APS underwent to a second Percutaneous transluminal coronary angioplasty due to rapid occlusion of stents placed in concomitant stenotic coronary arteries. Conclusions: From this study it was found that Antiphospholipid syndrome in relatively young patients hospitalised for Acute myocardial infarction is a concomitant- causing disorder in a quarter of the patients included in our study. This implies that in young patients it should be kept in mind that APS could be the reason of the problem. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2018-eular.7227 Citation: Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page A724Session: SLE, Sjögren’s and APS – clinical aspects (other than treatment)